Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Receivables (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Receivables for 7 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 370.04% to $2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 million, a 370.04% increase, with the full-year FY2024 number at $430000.0, up 112.87% from a year prior.
  • Receivables was $2.1 million for Q3 2025 at Vivos Therapeutics, up from $1.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $3.8 million in Q3 2021 to a low of $202000.0 in Q4 2023.
  • A 5-year average of $1.1 million and a median of $718000.0 in 2025 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 77.41% in 2022, then soared 370.04% in 2025.
  • Vivos Therapeutics' Receivables stood at $1.2 million in 2021, then crashed by 62.01% to $457000.0 in 2022, then crashed by 55.8% to $202000.0 in 2023, then soared by 112.87% to $430000.0 in 2024, then soared by 396.28% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Receivables are $2.1 million (Q3 2025), $1.6 million (Q2 2025), and $718000.0 (Q1 2025).